AGBL2 and rheumatoid arthritis: After adjustment of age and disease duration together with the absence of collinearity (VIF and tolerance were 1.03 and 0.97 respectively) and other related co-variables (Table 4), the positivity of anti-CCP2 remained a risk factor for ILD in RA patients (adjusted odds ratio [aOR] 3.50; 95% CI 1.52–8.04, p<0.001), regardless of the level of anti-CCP.